Lee Y.-C.CHIEN-CHING HUNGTsai M.-S.Zhang J.-Y.Wu P.-Y.Yang S.-P.Luo Y.-Z.Chang H.-Y.Liu W.-C.HSIN-YUN SUNSHAN-CHWEN CHANG2020-12-292020-12-2920181684-1182https://www.scopus.com/inward/record.uri?eid=2-s2.0-84977469605&doi=10.1016%2fj.jmii.2016.04.011&partnerID=40&md5=c5f819f8cc2a8fba1814bba97e5500d0https://scholars.lib.ntu.edu.tw/handle/123456789/535334Background/Purpose: To obtain current epidemiological data for better vaccination policies, this study aimed to assess the incidence and risk factors of herpes zoster in human immunodeficiency virus (HIV)-positive patients initiating combination antiretroviral therapy (cART) in Taiwan. Methods: Between June, 2012 and May, 2015, we prospectively identified zoster cases in HIV-positive patients initiating cART. Clinical information was collected on demographics, prior zoster, plasma HIV-1 RNA load (PVL), and CD4 count at baseline and during follow up. A case–control study by 1:2 matched pairs was used to identify the risk factors for zoster development. Results: During the 3-year study period, 826 patients with a mean age of 32.9 years were included, and 7.7% had prior zoster. The mean baseline CD4 count and PVL were 286 cells/μL and 4.90 log10 copies/mL, respectively. Fifty-four (6.5%) patients developed zoster after initiation of cART, with 43 episodes (79.6%) occurring within 1 year of cART initiation, which corresponded to an overall incidence rate of 3.61/100 person-years. The multivariate analysis revealed that prior zoster (adjusted odds ratio = 3.143; 95% confidence interval, 1.385–7.133) and baseline CD4 count < 200 cells/μL (adjusted odds ratio = 2.034; 95% confidence interval, 1.020–4.057) were independent risk factors for zoster in HIV-positive patients initiating cART. In case–control study, prior zoster and baseline PVL > 5 log10 copies/mL were risk factors for zoster development after cART initiation in multivariate analysis. Conclusions: Herpes zoster occurred in 6.5% of HIV-positive Taiwanese patients after initiation of cART, which was associated with prior zoster and baseline CD4 count < 200 cells/μL or baseline PVL > 5 log10 copies/mL. ? 2016[SDGs]SDG3atazanavir; integrase inhibitor; lamivudine plus zidovudine; nonnucleoside reverse transcriptase inhibitor; proteinase inhibitor; RNA directed DNA polymerase inhibitor; virus RNA; antiretrovirus agent; adult; antiretroviral therapy; Article; case control study; CD4 lymphocyte count; clinical assessment; cohort analysis; controlled study; drug substitution; drug withdrawal; epidemiological data; female; follow up; herpes zoster; human; Human immunodeficiency virus; Human immunodeficiency virus 1; Human immunodeficiency virus infected patient; Human immunodeficiency virus infection; incidence; infection risk; longitudinal study; major clinical study; male; medical information; prospective study; risk assessment; risk factor; Taiwan; treatment duration; vaccination; combination drug therapy; complication; herpes zoster; highly active antiretroviral therapy; Human immunodeficiency virus infection; incidence; pathogenicity; Varicella zoster virus; virus load; young adult; Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Case-Control Studies; CD4 Lymphocyte Count; Cohort Studies; Drug Therapy, Combination; Female; Herpes Zoster; Herpesvirus 3, Human; HIV Infections; Humans; Incidence; Male; Risk Factors; Taiwan; Viral Load; Young Adultjournal article10.1016/j.jmii.2016.04.01127329131